- Home
- VTYX vs FLL Comparison
VTYX vs FLL Comparison
Compare VTYX & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- FLL
- Stock Information
- Founded
- VTYX 2018
- FLL 1987
- Country
- VTYX United States
- FLL United States
- Employees
- VTYX N/A
- FLL N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- FLL Hotels/Resorts
- Sector
- VTYX Health Care
- FLL Consumer Discretionary
- Exchange
- VTYX Nasdaq
- FLL Nasdaq
- Market Cap
- VTYX 154.9M
- FLL 116.4M
- IPO Year
- VTYX 2021
- FLL 1993
- Fundamental
- Price
- VTYX $1.17
- FLL $3.30
- Analyst Decision
- VTYX Buy
- FLL Strong Buy
- Analyst Count
- VTYX 4
- FLL 4
- Target Price
- VTYX $11.33
- FLL $6.25
- AVG Volume (30 Days)
- VTYX 965.2K
- FLL 165.3K
- Earning Date
- VTYX 05-16-2025
- FLL 05-08-2025
- Dividend Yield
- VTYX N/A
- FLL N/A
- EPS Growth
- VTYX N/A
- FLL N/A
- EPS
- VTYX N/A
- FLL N/A
- Revenue
- VTYX N/A
- FLL $292,065,000.00
- Revenue This Year
- VTYX N/A
- FLL $10.53
- Revenue Next Year
- VTYX N/A
- FLL $7.53
- P/E Ratio
- VTYX N/A
- FLL N/A
- Revenue Growth
- VTYX N/A
- FLL 21.16
- 52 Week Low
- VTYX $0.78
- FLL $2.86
- 52 Week High
- VTYX $5.66
- FLL $5.90
- Technical
- Relative Strength Index (RSI)
- VTYX 46.01
- FLL 47.55
- Support Level
- VTYX $1.05
- FLL $3.06
- Resistance Level
- VTYX $1.48
- FLL $3.40
- Average True Range (ATR)
- VTYX 0.11
- FLL 0.24
- MACD
- VTYX 0.01
- FLL 0.06
- Stochastic Oscillator
- VTYX 27.91
- FLL 54.32
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.